z-logo
open-access-imgOpen Access
Downregulation of the GHRH/GH/IGF-1 axis in a mouse model of Börjeson-Forssman-Lehman Syndrome
Author(s) -
Helen M. McRae,
Samantha Eccles,
Lachlan Whitehead,
Warren S. Alexander,
Jozef Gécz,
Tim Thomas,
Anne K. Voss
Publication year - 2020
Publication title -
development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.754
H-Index - 325
eISSN - 1477-9129
pISSN - 0950-1991
DOI - 10.1242/dev.187021
Subject(s) - biology , endocrinology , socs2 , medicine , downregulation and upregulation , hypothalamus , short stature , growth hormone–releasing hormone , phenotype , growth factor , homeobox , endocrine system , hormone , regulator , growth hormone , gene , receptor , gene expression , genetics , suppressor
The Börjeson–Forssman–Lehmann syndrome (BFLS) is an intellectual disability and endocrine disorder caused by plant homeodomain finger 6 (PHF6) mutations. BFLS patients present with short stature. We report a mouse model of BFLS, in which deletion of Phf6 causes a proportional reduction in body size compared to control mice. Growth hormone (GH) levels were reduced in the absence of PHF6. Phf6−/Y animals displayed a reduction in the expression of the genes encoding GH releasing hormone (GHRH) in the brain, GH in the pituitary gland and insulin-like growth factor-1 (IGF-1) in the liver. Phf6 deletion specifically in the nervous system caused a proportional growth defect, indicating neuroendocrine contribution to the phenotype. Loss of suppressor of cytokine signaling 2 (SOCS2), a negative regulator of growth hormone signaling partially rescued body size, supporting a reversible deficiency in GH signaling. These results demonstrate that PHF6 regulates the GHRH/GH/IGF-1 axis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom